The stock of TransCode Therapeutics Inc (RNAZ) has gone up by 8.60% for the week, with a -43.54% drop in the past month and a 39.65% rise in the past quarter. The volatility ratio for the week is 11.06%, and the volatility levels for the past 30 days are 11.74% for RNAZ. The simple moving average for the past 20 days is -13.88% for RNAZ’s stock, with a -42.68% simple moving average for the past 200 days.
Is It Worth Investing in TransCode Therapeutics Inc (NASDAQ: RNAZ) Right Now?
The 36-month beta value for RNAZ is at 0.59. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RNAZ is 17.24M, and currently, shorts hold a 4.31% of that float. The average trading volume for RNAZ on November 22, 2024 was 1.66M shares.
RNAZ) stock’s latest price update
TransCode Therapeutics Inc (NASDAQ: RNAZ)’s stock price has gone rise by 13.03 in comparison to its previous close of 0.34, however, the company has experienced a 8.60% increase in its stock price over the last five trading days. globenewswire.com reported 2024-11-05 that BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from The Nasdaq Stock Market LLC (Nasdaq) that the Nasdaq Hearings Panel before which TransCode appeared on October 1, 2024, has determined to grant TransCode’s request to continue its listing on The Nasdaq Stock Market subject to certain conditions to regain compliance. The Panel has also issued a Public Reprimand Letter in accordance with Listing Rule 5815(c)(1)(D).
RNAZ Trading at -23.90% from the 50-Day Moving Average
After a stumble in the market that brought RNAZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.96% of loss for the given period.
Volatility was left at 11.74%, however, over the last 30 days, the volatility rate increased by 11.06%, as shares sank -41.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +50.20% upper at present.
During the last 5 trading sessions, RNAZ rose by +8.60%, which changed the moving average for the period of 200-days by -36.69% in comparison to the 20-day moving average, which settled at $0.4413. In addition, TransCode Therapeutics Inc saw -94.24% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RNAZ
Current profitability levels for the company are sitting at:
- -19.47 for the present operating margin
- 0.44 for the gross margin
The net margin for TransCode Therapeutics Inc stands at -19.82. The total capital return value is set at -8.88. Equity return is now at value -490.03, with -210.77 for asset returns.
Currently, EBITDA for the company is -17.97 million with net debt to EBITDA at 0.12. When we switch over and look at the enterprise to sales, we see a ratio of 6.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.58.
Conclusion
In conclusion, TransCode Therapeutics Inc (RNAZ) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
